CYTK  valuation analysis

Name: Cytokinetics, Incorporated
Description: Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. (more)
Industry: Biotechnology
Last 10Q10Qs are quarterly reports which contain a company's financial figures. We use these to calculate the FFER.: Feb 25, 2021
Market cap: $1.73B (659th)
Sales(TTM): $55.83M (837th)
Earnings(TTM): -$127.29M (745th)

FFER: 1.74*
Actual price: $24.32
* Earnings were reported May 04, 2021 but we do not have the financials for this quarter. This is likely because the company has not yet released them. However, it might also be a problem with data quality. Regardless, you should take the FFER above with a grain of salt until we get updated financials.

Prices as of EOD 2021-05-12
Price & Estimates
Sales & Earnings history (TTM)
  • Cytokinetics, Incorporated's sales grew by 107.8% ($26.87M to $55.83M) over one year against a market average growth of 3.5%.
Earnings / MarketCap
Cytokinetics, Incorporated
"Biotechnology" industry
Sales / MarketCap
Cytokinetics, Incorporated
"Biotechnology" industry
Book / MarketCap
Cytokinetics, Incorporated
"Biotechnology" industry
Equity / Assets
Cytokinetics, Incorporated
"Biotechnology" industry